

# Robin M Warren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/354978/publications.pdf>

Version: 2024-02-01

173  
papers

10,352  
citations

41323

49  
h-index

38368

95  
g-index

178  
all docs

178  
docs citations

178  
times ranked

8447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of <i>Mycobacterium bovis</i> infection in free-ranging common hippopotamus ( <i>Hippopotamus amphibius</i> ). <i>Journal of Veterinary Diagnostic Investigation</i> , 2022, 34, 61-67.	1.3	5
2	Improved detection of <i>Mycobacterium tuberculosis</i> and <i>M. bovis</i> in African wildlife samples using cationic peptide decontamination and mycobacterial culture supplementation. <i>Journal of Veterinary Diagnostic Investigation</i> , 2022, 34, 61-67.	0.5	11
3	Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in <i>Mycobacterium tuberculosis</i> . <i>Journal of Clinical Microbiology</i> , 2022, 60, JCM0190721.	1.8	6
4	COVID-19 detection in cough, breath and speech using deep transfer learning and bottleneck features. <i>Computers in Biology and Medicine</i> , 2022, 141, 105153.	3.9	56
5	Optimizing liquefaction and decontamination of sputum for DNA extraction from <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2022, 132, 102159.	0.8	6
6	Frequent Suboptimal Thermocycler Ramp Rate Usage Negatively Impacts GenoType MTBDRsl VER 2.0 Performance for Second-Line Drug-Resistant Tuberculosis Diagnosis. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 494-502.	1.2	4
7	Transmission Of Tuberculosis Among illicit drug use Linkages (TOTAL): A cross-sectional observational study protocol using respondent driven sampling. <i>PLoS ONE</i> , 2022, 17, e0262440.	1.1	1
8	An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NEXt Study). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1214-1227.	2.5	38
9	A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 56.	1.5	7
10	Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0236221.	1.8	14
11	Ancient and recent differences in the intrinsic susceptibility of <i>Mycobacterium tuberculosis</i> complex to pretomanid. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1685-1693.	1.3	34
12	Localization of EccA3 at the growing pole in <i>Mycobacterium smegmatis</i> . <i>BMC Microbiology</i> , 2022, 22, 140.	1.3	1
13	High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. <i>HIV Medicine</i> , 2022, 23, 1085-1097.	1.0	2
14	Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with <i>Mycobacterium tuberculosis</i> Lineage. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
15	Adaptation and Diagnostic Potential of a Commercial Cat Interferon Gamma Release Assay for the Detection of <i>Mycobacterium bovis</i> Infection in African Lions ( <i>Panthera leo</i> ). <i>Pathogens</i> , 2022, 11, 765.	1.2	5
16	Optimized interferon-gamma release assays for detection of <i>Mycobacterium bovis</i> infection in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2021, 231, 110163.	0.5	6
17	Use of the MILLIPLEX <sup>®</sup> bovine cytokine/chemokine multiplex assay to identify <i>Mycobacterium bovis</i> -infection biomarkers in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2021, 231, 110152.	0.5	3
18	Cytokine biomarker discovery in the white rhinoceros ( <i>Ceratotherium simum</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2021, 232, 110168.	0.5	2

#	ARTICLE	IF	CITATIONS
19	Review of Diagnostic Tests for Detection of Mycobacterium bovis Infection in South African Wildlife. <i>Frontiers in Veterinary Science</i> , 2021, 8, 588697.	0.9	31
20	Human whole genome sequencing in South Africa. <i>Scientific Reports</i> , 2021, 11, 606.	1.6	10
21	Cell-Mediated Immunological Biomarkers and Their Diagnostic Application in Livestock and Wildlife Infected With Mycobacterium bovis. <i>Frontiers in Immunology</i> , 2021, 12, 639605.	2.2	12
22	Optimisation of the tuberculin skin test for detection of Mycobacterium bovis in African buffaloes ( <i>Syncerus caffer</i> ). <i>Preventive Veterinary Medicine</i> , 2021, 188, 105254.	0.7	6
23	Novel molecular transport medium used in combination with Xpert MTB/RIF ultra provides rapid detection of Mycobacterium bovis in African buffaloes. <i>Scientific Reports</i> , 2021, 11, 7061.	1.6	13
24	Face masks in the post-COVID-19 era: a silver lining for the damaged tuberculosis public health response?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 340-342.	5.2	20
25	Development of a cytokine gene expression assay for the relative quantification of the African elephant ( <i>Loxodonta africana</i> ) cell-mediated immune responses. <i>Cytokine</i> , 2021, 141, 155453.	1.4	1
26	Anaerobe-enriched gut microbiota predicts pro-inflammatory responses in pulmonary tuberculosis. <i>EBioMedicine</i> , 2021, 67, 103374.	2.7	22
27	Alcohol and Tobacco Use in a Tuberculosis Treatment Cohort during South Africa's COVID-19 Sales Bans: A Case Series. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5449.	1.2	10
28	Directly Observed Therapy to Measure Adherence to Tuberculosis Medication in Observational Research: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2021, 10, e24510.	0.5	0
29	Melting the <i>is6110</i> Promoter Variants: Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New <i>is6110</i> Promoter Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0250220.	1.4	0
30	A multi-phenotype genome-wide association study of clades causing tuberculosis in a Ghanaian- and South African cohort. <i>Genomics</i> , 2021, 113, 1802-1815.	1.3	8
31	Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0036421.	1.4	7
32	COVID-19 cough classification using machine learning and global smartphone recordings. <i>Computers in Biology and Medicine</i> , 2021, 135, 104572.	3.9	171
33	Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. <i>Lancet Microbe</i> , 2021, 2, e584-e593.	3.4	9
34	Drug resistant tuberculosis cases from the Copperbelt province and Northern regions of Zambia: Genetic diversity, demographic and clinical characteristics. <i>Tuberculosis</i> , 2021, 130, 102122.	0.8	1
35	Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1351.e1-1351.e4.	2.8	6
36	Automatic cough classification for tuberculosis screening in a real-world environment. <i>Physiological Measurement</i> , 2021, 42, 105014.	1.2	34

#	ARTICLE	IF	CITATIONS
37	Comprehensive and accurate genetic variant identification from contaminated and low-coverage <i>Mycobacterium tuberculosis</i> whole genome sequencing data. <i>Microbial Genomics</i> , 2021, 7, .	1.0	10
38	CYTOKINE-RELEASE ASSAY FOR THE DETECTION OF <i>MYCOBACTERIUM BOVIS</i> INFECTION IN CHEETAH ( <i>ACINONYX JUBATUS</i> ). <i>Journal of Zoo and Wildlife Medicine</i> , 2021, 52, 1113-1122.	0.3	2
39	Identification of gene fusion events in <i>Mycobacterium tuberculosis</i> that encode chimeric proteins. <i>NAR Genomics and Bioinformatics</i> , 2020, 2, lqaa033.	1.5	3
40	MDR <i>M. tuberculosis</i> outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. <i>Genome Medicine</i> , 2020, 12, 104.	3.6	50
41	The Xpert MTB/RIF Ultra assay detects <i>Mycobacterium tuberculosis</i> complex DNA in white rhinoceros ( <i>Ceratotherium simum</i> ) and African elephants ( <i>Loxodonta africana</i> ). <i>Scientific Reports</i> , 2020, 10, 14482.	1.6	22
42	Genetic Diversity in <i>Mycobacterium tuberculosis</i> Clinical Isolates and Resulting Outcomes of Tuberculosis Infection and Disease. <i>Annual Review of Genetics</i> , 2020, 54, 511-537.	3.2	22
43	Evidence for the Effect of Vaccination on Host-Pathogen Interactions in a Murine Model of Pulmonary Tuberculosis by <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Immunology</i> , 2020, 11, 930.	2.2	8
44	Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. <i>Nature Medicine</i> , 2020, 26, 1435-1443.	15.2	38
45	The VetMAX <sup>®</sup> , <i>M. tuberculosis</i> complex PCR kit detects MTBC DNA in antemortem and postmortem samples from white rhinoceros ( <i>Ceratotherium simum</i> ), African elephants ( <i>Loxodonta africana</i> ) and African buffaloes ( <i>Syncerus caffer</i> ). <i>BMC Veterinary Research</i> , 2020, 16, 220.	0.7	9
46	Xpert <i>Mycobacterium tuberculosis</i> /Rifampicin <sup>®</sup> Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. <i>Clinical Infectious Diseases</i> , 2020, 73, e362-e370.	2.9	11
47	Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes. <i>Scientific Reports</i> , 2020, 10, 1917.	1.6	11
48	Extract from used Xpert MTB/RIF Ultra cartridges is useful for accurate second-line drug-resistant tuberculosis diagnosis with minimal rpoB-amplicon cross-contamination risk. <i>Scientific Reports</i> , 2020, 10, 2633.	1.6	6
49	Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 368-382.	5.2	58
50	Phylogenomic assessment of drug-resistant <i>Mycobacterium tuberculosis</i> strains from Beira, Mozambique. <i>Tuberculosis</i> , 2020, 121, 101905.	0.8	3
51	Discordances between molecular assays for rifampicin resistance in <i>Mycobacterium tuberculosis</i> : frequency, mechanisms and clinical impact. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1123-1129.	1.3	9
52	Identifying nucleic acid-associated proteins in <i>Mycobacterium smegmatis</i> by mass spectrometry-based proteomics. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 19.	1.0	7
53	Spatial distribution of <i>Mycobacterium Tuberculosis</i> in metropolitan Harare, Zimbabwe. <i>PLoS ONE</i> , 2020, 15, e0231637.	1.1	15
54	Test Characteristics of Assays to Detect Infection in High-Prevalence African Buffalo ( <i>Syncerus caffer</i> ) Herds. <i>Journal of Wildlife Diseases</i> , 2020, 56, 462-465.	0.3	2

#	ARTICLE	IF	CITATIONS
55	Distinct serum biosignatures are associated with different tuberculosis treatment outcomes. <i>Tuberculosis</i> , 2019, 118, 101859.	0.8	24
56	Impact of <i>Mycobacterium bovis</i> -induced pathology on interpretation of QuantiFERON®-TB Gold assay results in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2019, 217, 109923.	0.5	8
57	Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting. <i>Infection, Genetics and Evolution</i> , 2019, 75, 103948.	1.0	13
58	An interferon-gamma release assay for the diagnosis of the <i>Mycobacterium bovis</i> infection in white rhinoceros ( <i>Ceratotherium simum</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2019, 217, 109931.	0.5	17
59	Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis. <i>PLoS ONE</i> , 2019, 14, e0223308.	1.1	5
60	Detection of Second Line Drug Resistance among Drug Resistant <i>Mycobacterium Tuberculosis</i> Isolates in Botswana. <i>Pathogens</i> , 2019, 8, 208.	1.2	9
61	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	5.2	92
62	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 370-380.	2.5	27
63	Fatal Tuberculosis in a Free-Ranging African Elephant and One Health Implications of Human Pathogens in Wildlife. <i>Frontiers in Veterinary Science</i> , 2019, 6, 18.	0.9	28
64	Whole genome sequencing of <i>Mycobacterium tuberculosis</i> : current standards and open issues. <i>Nature Reviews Microbiology</i> , 2019, 17, 533-545.	13.6	237
65	Evolution of rifampicin treatment for tuberculosis. <i>Infection, Genetics and Evolution</i> , 2019, 74, 103937.	1.0	61
66	Parallel measurement of IFN- $\gamma$ and IP-10 in QuantiFERON®-TB Gold (QFT) plasma improves the detection of <i>Mycobacterium bovis</i> infection in African buffaloes ( <i>Syncerus caffer</i> ). <i>Preventive Veterinary Medicine</i> , 2019, 169, 104700.	0.7	16
67	Genetic diversity of <i>Mycobacterium tuberculosis</i> strains circulating in Botswana. <i>PLoS ONE</i> , 2019, 14, e0216306.	1.1	9
68	A commercial ELISA for detection of interferon gamma in white rhinoceros. <i>Journal of Veterinary Diagnostic Investigation</i> , 2019, 31, 531-536.	0.5	11
69	The microbiome and tuberculosis: state of the art, potential applications, and defining the clinical research agenda. <i>Lancet Respiratory Medicine</i> , 2019, 7, 892-906.	5.2	62
70	Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1278-1287.	2.9	16
71	Cytokine gene expression assay as a diagnostic tool for detection of <i>Mycobacterium bovis</i> infection in warthogs ( <i>Phacochoerus africanus</i> ). <i>Scientific Reports</i> , 2019, 9, 16525.	1.6	7
72	Minority <i>Mycobacterium tuberculosis</i> Genotypic Populations as an Indicator of Subsequent Phenotypic Resistance. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 61, 789-791.	1.4	11

#	ARTICLE	IF	CITATIONS
73	Transmission of drug-resistant tuberculosis in HIV-endemic settings. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e77-e88.	4.6	47
74	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	19
75	Regulatory T Cells Subvert Mycobacterial Containment in Patients Failing Extensively Drug-Resistant Tuberculosis Treatment. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 104-116.	2.5	28
76	Mycobacterial nucleoid associated proteins: An added dimension in gene regulation. <i>Tuberculosis</i> , 2018, 108, 169-177.	0.8	26
77	Mutations in ppe38 block PE_PGRS secretion and increase virulence of <i>Mycobacterium tuberculosis</i> . <i>Nature Microbiology</i> , 2018, 3, 181-188.	5.9	112
78	False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	78
79	Measuring antigen-specific responses in <i>Mycobacterium bovis</i> -infected warthogs ( <i>Phacochoerus</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	10
80	A New Phylogenetic Framework for the Animal-Adapted <i>Mycobacterium tuberculosis</i> Complex. <i>Frontiers in Microbiology</i> , 2018, 9, 2820.	1.5	145
81	The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2667-2674.	1.3	17
82	Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. <i>BMC Infectious Diseases</i> , 2018, 18, 488.	1.3	30
83	Parallel testing increases detection of <i>Mycobacterium bovis</i> -infected African buffaloes ( <i>Syncerus</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock 13	0.5	13
84	Integrating standardized whole genome sequence analysis with a global <i>Mycobacterium tuberculosis</i> antibiotic resistance knowledgebase. <i>Scientific Reports</i> , 2018, 8, 15382.	1.6	75
85	Diagnostic Accuracy and Utility of FluoroType MTBDR, a New Molecular Assay for Multidrug-Resistant Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	33
86	IP-10: A potential biomarker for detection of <i>Mycobacterium bovis</i> infection in warthogs ( <i>Phacochoerus africanus</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2018, 201, 43-48.	0.5	13
87	Mixed <i>Mycobacterium tuberculosis</i> "Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. <i>Journal of Infectious Diseases</i> , 2018, 218, 1974-1982.	1.9	32
88	Rv1460, a SufR homologue, is a repressor of the suf operon in <i>Mycobacterium tuberculosis</i> . <i>PLoS ONE</i> , 2018, 13, e0200145.	1.1	26
89	Unexpected Genomic and Phenotypic Diversity of <i>Mycobacterium africanum</i> Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity. <i>Genome Biology and Evolution</i> , 2018, 10, 1858-1874.	1.1	47
90	Geospatial distribution of <i>Mycobacterium tuberculosis</i> genotypes in Africa. <i>PLoS ONE</i> , 2018, 13, e0200632.	1.1	54

#	ARTICLE	IF	CITATIONS
91	Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: A retrospective spatiotemporal analysis. <i>PLoS Medicine</i> , 2018, 15, e1002638.	3.9	8
92	Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1208-1219.	2.5	130
93	Isoniazid Resistance and Dosage as Treatment for Patients with Tuberculosis. <i>Current Drug Metabolism</i> , 2018, 18, 1030-1039.	0.7	11
94	Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1502-1508.	2.9	17
95	Progenitor strain introduction of <i>Mycobacterium bovis</i> at the wildlife-livestock interface can lead to clonal expansion of the disease in a single ecosystem. <i>Infection, Genetics and Evolution</i> , 2017, 51, 235-238.	1.0	35
96	Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2017, 65, 1206-1211.	2.9	13
97	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 291-360.	5.2	459
98	Proteogenomic Investigation of Strain Variation in Clinical <i>Mycobacterium tuberculosis</i> Isolates. <i>Journal of Proteome Research</i> , 2017, 16, 3841-3851.	1.8	27
99	<i>Mycobacterium tuberculosis</i> Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	38
100	Exploring the potential of T7 bacteriophage protein Gp2 as a novel inhibitor of mycobacterial RNA polymerase. <i>Tuberculosis</i> , 2017, 106, 82-90.	0.8	4
101	<i>Mycobacterium tuberculosis</i> genomic DNA from used Xpert MTB/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping. <i>Scientific Reports</i> , 2017, 7, 14854.	1.6	11
102	A standardised method for interpreting the association between mutations and phenotypic drug resistance in <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2017, 50, 1701354.	3.1	273
103	Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence. <i>Journal of Infectious Diseases</i> , 2017, 216, 632-640.	1.9	9
104	Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2017, 5, 269-281.	5.2	106
105	Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1532-1540.	2.5	105
106	The stability of plasma IP-10 enhances its utility for the diagnosis of <i>Mycobacterium bovis</i> infection in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2016, 173, 17-20.	0.5	10
107	Implementation of new tools for multidrug-resistant tuberculosis detection and control. <i>International Journal of Mycobacteriology</i> , 2016, 5, S67.	0.3	2
108	Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2016, 99, 128-130.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Genetic Determinants of Drug Resistance in <i>Mycobacterium tuberculosis</i> and Their Diagnostic Value. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 621-630.	2.5	131
110	Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 17-26.	1.3	123
111	Mapping of <i>Mycobacterium tuberculosis</i> Complex Genetic Diversity Profiles in Tanzania and Other African Countries. <i>PLoS ONE</i> , 2016, 11, e0154571.	1.1	41
112	MDR tuberculosis control: time to change the dogma?. <i>Lancet Respiratory Medicine</i> , 2015, 3, 907-909.	5.2	5
113	High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis. <i>PLoS ONE</i> , 2015, 10, e0123655.	1.1	19
114	A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0133869.	1.1	105
115	Genetic diversity of <i>Mycobacterium tuberculosis</i> isolated from tuberculosis patients in the Serengeti ecosystem in Tanzania. <i>Tuberculosis</i> , 2015, 95, 170-178.	0.8	24
116	Iron acquisition strategies in mycobacteria. <i>Tuberculosis</i> , 2015, 95, 123-130.	0.8	53
117	Assessing the progress of <i>Mycobacterium tuberculosis</i> H37Rv structural genomics. <i>Tuberculosis</i> , 2015, 95, 131-136.	0.8	12
118	Evolutionary history and global spread of the <i>Mycobacterium tuberculosis</i> Beijing lineage. <i>Nature Genetics</i> , 2015, 47, 242-249.	9.4	466
119	Phosphoproteomics analysis of a clinical <i>Mycobacterium tuberculosis</i> Beijing isolate: expanding the mycobacterial phosphoproteome catalog. <i>Frontiers in Microbiology</i> , 2015, 6, 6.	1.5	65
120	Association of toll-like receptors with susceptibility to tuberculosis suggests sex-specific effects of TLR8 polymorphisms. <i>Infection, Genetics and Evolution</i> , 2015, 34, 221-229.	1.0	69
121	<i>Mycobacterium tuberculosis</i> <i>pncA</i> Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3633-3635.	1.8	35
122	Molecular Epidemiological Interpretation of the Epidemic of Extensively Drug-Resistant Tuberculosis in South Africa. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3650-3653.	1.8	11
123	Whole genome sequence analysis of <i>Mycobacterium suricattae</i> . <i>Tuberculosis</i> , 2015, 95, 682-688.	0.8	52
124	The Risk of Tuberculosis Reinfection Soon after Cure of a First Disease Episode Is Extremely High in a Hyperendemic Community. <i>PLoS ONE</i> , 2015, 10, e0144487.	1.1	19
125	Fighting an old disease with next-generation sequencing. <i>ELife</i> , 2015, 4, .	2.8	2
126	The evaluation of candidate biomarkers of cell-mediated immunity for the diagnosis of <i>Mycobacterium bovis</i> infection in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2014, 162, 198-202.	0.5	15



#	ARTICLE	IF	CITATIONS
127	Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. <i>Lancet</i> , The, 2014, 383, 1230-1239.	6.3	211
128	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 321-338.	5.2	237
129	The Temporal Dynamics of Relapse and Reinfection Tuberculosis After Successful Treatment: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 1676-1683.	2.9	119
130	Rapid Sequencing of the <i>Mycobacterium tuberculosis</i> <i>pncA</i> Gene for Detection of Pyrazinamide Susceptibility. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4056-4057.	1.8	17
131	Agreement between assays of cell-mediated immunity utilizing <i>Mycobacterium bovis</i> -specific antigens for the diagnosis of tuberculosis in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2014, 160, 133-138.	0.5	46
132	Novel Cause of Tuberculosis in Meerkats, South Africa. <i>Emerging Infectious Diseases</i> , 2013, 19, 2004-2007.	2.0	81
133	Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa. <i>PLoS ONE</i> , 2013, 8, e63057.	1.1	71
134	Programmatically Selected Multidrug-Resistant Strains Drive the Emergence of Extensively Drug-Resistant Tuberculosis in South Africa. <i>PLoS ONE</i> , 2013, 8, e70919.	1.1	44
135	Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study. <i>PLoS ONE</i> , 2013, 8, e83480.	1.1	45
136	The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks. <i>PLoS ONE</i> , 2013, 8, e59414.	1.1	61
137	Population Structure of Mixed <i>Mycobacterium tuberculosis</i> Infection Is Strain Genotype and Culture Medium Dependent. <i>PLoS ONE</i> , 2013, 8, e70178.	1.1	57
138	Mixed-Strain <i>Mycobacterium tuberculosis</i> Infections and the Implications for Tuberculosis Treatment and Control. <i>Clinical Microbiology Reviews</i> , 2012, 25, 708-719.	5.7	172
139	Population Structure of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> Strains in South Africa. <i>Journal of Clinical Microbiology</i> , 2012, 50, 995-1002.	1.8	50
140	Mutations in the <i>rrsA1401G</i> Gene and Phenotypic Resistance to Amikacin and Capreomycin in <i>Mycobacterium tuberculosis</i> . <i>Microbial Drug Resistance</i> , 2012, 18, 193-197.	0.9	60
141	Comparative Analysis of <i>Mycobacterium tuberculosis</i> <i>pe</i> and <i>ppe</i> Genes Reveals High Sequence Variation and an Apparent Absence of Selective Constraints. <i>PLoS ONE</i> , 2012, 7, e30593.	1.1	83
142	<i>gyrA</i> mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1088-1093.	1.3	107
143	Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. <i>Infection, Genetics and Evolution</i> , 2012, 12, 686-694.	1.0	62
144	Chapter 9: Tuberculosis Recurrence: Exogenous or Endogenous?. <i>Progress in Respiratory Research</i> , 2011, , 73-80.	0.1	1

#	ARTICLE	IF	CITATIONS
145	Modification of the QuantiFERON-TB Gold (In-Tube) assay for the diagnosis of <i>Mycobacterium bovis</i> infection in African buffaloes ( <i>Syncerus caffer</i> ). <i>Veterinary Immunology and Immunopathology</i> , 2011, 142, 113-118.	0.5	34
146	The non-clonality of drug resistance in Beijing-genotype isolates of <i>Mycobacterium tuberculosis</i> from the Western Cape of South Africa. <i>BMC Genomics</i> , 2010, 11, 670.	1.2	69
147	Emergence of Increased Resistance and Extensively Drug-Resistant Tuberculosis Despite Treatment Adherence, South Africa. <i>Emerging Infectious Diseases</i> , 2010, 16, 264-271.	2.0	113
148	Molecular Detection of Mixed Infections of <i>Mycobacterium tuberculosis</i> Strains in Sputum Samples from Patients in Karonga District, Malawi. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4512-4518.	1.8	57
149	Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. <i>Lancet, The</i> , 2010, 375, 1798-1807.	6.3	225
150	Potential of Rapid Diagnosis for Controlling Drug-Susceptible and Drug-Resistant Tuberculosis in Communities Where <i>Mycobacterium tuberculosis</i> Infections Are Highly Prevalent. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1484-1490.	1.8	39
151	The clinical relevance of <i>Mycobacterial</i> pharmacogenetics. <i>Tuberculosis</i> , 2009, 89, 199-202.	0.8	37
152	Multiple, independent, identical IS6110 insertions in <i>Mycobacterium tuberculosis</i> PPE genes. <i>Tuberculosis</i> , 2009, 89, 439-442.	0.8	11
153	Detection of <i>Mycobacterium tuberculosis</i> infection in chacma baboons ( <i>Papio ursinus</i> ) using the QuantiFERON-TB Gold (In-Tube) assay. <i>Journal of Medical Primatology</i> , 2009, 38, 411-417.	0.3	20
154	Insertion Element IS6110-Based Restriction Fragment Length Polymorphism Genotyping of <i>Mycobacterium tuberculosis</i> . <i>Methods in Molecular Biology</i> , 2009, 465, 353-370.	0.4	7
155	Antimicrobial resistance in tuberculosis: an international perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 759-766.	2.0	19
156	<i>Mycobacterium tuberculosis</i> complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. <i>BMC Microbiology</i> , 2006, 6, 23.	1.3	900
157	Safe <i>Mycobacterium tuberculosis</i> DNA Extraction Method That Does Not Compromise Integrity. <i>Journal of Clinical Microbiology</i> , 2006, 44, 254-256.	1.8	66
158	Differentiation of <i>Mycobacterium tuberculosis</i> complex by PCR amplification of genomic regions of difference. <i>International Journal of Tuberculosis and Lung Disease</i> , 2006, 10, 818-22.	0.6	186
159	Reinfection and Mixed Infection Cause Changing <i>Mycobacterium tuberculosis</i> Drug-Resistance Patterns. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 636-642.	2.5	173
160	Rate of Reinfection Tuberculosis after Successful Treatment Is Higher than Rate of New Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 171, 1430-1435.	2.5	371
161	Clonal Expansion of a Globally Disseminated Lineage of <i>Mycobacterium tuberculosis</i> with Low IS 6110 Copy Numbers. <i>Journal of Clinical Microbiology</i> , 2004, 42, 5774-5782.	1.8	42
162	Molecular Characteristics and Global Spread of <i>Mycobacterium tuberculosis</i> with a Western Cape F11 Genotype. <i>Journal of Clinical Microbiology</i> , 2004, 42, 769-772.	1.8	46

#	ARTICLE	IF	CITATIONS
163	Patients with Active Tuberculosis often Have Different Strains in the Same Sputum Specimen. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 610-614.	2.5	267
164	Proportion of tuberculosis transmission that takes place in households in a high-incidence area. Lancet, The, 2004, 363, 212-214.	6.3	261
165	Molecular Detection of Early Appearance of Drug Resistance during Mycobacterium tuberculosis Infection. Clinical Chemistry and Laboratory Medicine, 2002, 40, 876-81.	1.4	12
166	Multiple Mycobacterium tuberculosis Strains in Early Cultures from Patients in a High-Incidence Community Setting. Journal of Clinical Microbiology, 2002, 40, 2750-2754.	1.8	73
167	Prediction of Drug Resistance in M. tuberculosis: Molecular Mechanisms, Tools, and Applications. IUBMB Life, 2002, 53, 231-237.	1.5	40
168	Analysis for a Limited Number of Gene Codons Can Predict Drug Resistance of Mycobacterium tuberculosis in a High-Incidence Community. Journal of Clinical Microbiology, 2001, 39, 636-641.	1.8	154
169	Classification of drug-resistant tuberculosis in an epidemic area. Lancet, The, 2000, 356, 22-25.	6.3	88
170	Transmission of a Multidrug-Resistant Mycobacterium tuberculosis Strain Resembling "Strain W" among Noninstitutionalized, Human Immunodeficiency Virus-Seronegative Patients. Journal of Infectious Diseases, 1999, 180, 1608-1615.	1.9	94
171	Exogenous Reinfection as a Cause of Recurrent Tuberculosis after Curative Treatment. New England Journal of Medicine, 1999, 341, 1174-1179.	13.9	561
172	The quantitation of biotinylated compounds by a solid-phase assay using a 125I-labelled biotin derivative. FEBS Letters, 1987, 215, 305-310.	1.3	5
173	TB Epidemiology and Human Genetics. Novartis Foundation Symposium, 0, , 17-41.	1.2	11